Long-term growth hormone therapy in mitochondrial cytopathy

Horm Res. 2004;62(2):103-6. doi: 10.1159/000080451. Epub 2004 Aug 25.

Abstract

Objective: To describe in a 5-year-old Caucasian male with mitochondrial cytopathy, a biochemical growth hormone (GH) deficiency associated with normal GH biological activity as evaluated by Nb2 cell bioassay and normal serum IGF-I and IGFBP3 values increasing slightly after GH administration.

Method: Serum GH concentrations were measured with a commercial immunofluorometric assay and with a biological assay, which uses the Nb2 cell line. Serum IGF-I and IGFBP3 concentrations were measured with RIA.

Results: The GH-supplementary therapy was initially effective in terms of growth gain, but no therapeutic benefit was observed over a long period of time.

Conclusion: In patients suffering from mitochondrial cytopathy, short stature seems to be attributed more to a disease-related inadequate protein substrate than to the non-classical GH deficiency.

Publication types

  • Case Reports

MeSH terms

  • Child, Preschool
  • Growth Disorders / drug therapy*
  • Growth Disorders / pathology
  • Hormone Replacement Therapy*
  • Human Growth Hormone / administration & dosage
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Male
  • Mitochondrial Diseases / drug therapy*
  • Mitochondrial Diseases / pathology

Substances

  • Human Growth Hormone